NO333744B1 - Farmasoytisk formulering omfattende et pyrimidin-A-onderivat belagt med en enterisk polymer og fremgangsmate for fremstilling derav - Google Patents
Farmasoytisk formulering omfattende et pyrimidin-A-onderivat belagt med en enterisk polymer og fremgangsmate for fremstilling derav Download PDFInfo
- Publication number
- NO333744B1 NO333744B1 NO20061514A NO20061514A NO333744B1 NO 333744 B1 NO333744 B1 NO 333744B1 NO 20061514 A NO20061514 A NO 20061514A NO 20061514 A NO20061514 A NO 20061514A NO 333744 B1 NO333744 B1 NO 333744B1
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical formulation
- formulation according
- core
- active ingredient
- enteric polymer
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 26
- 238000000034 method Methods 0.000 title abstract description 12
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims description 31
- 238000000576 coating method Methods 0.000 claims description 27
- 239000011248 coating agent Substances 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 10
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 10
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 5
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 5
- 229960004977 anhydrous lactose Drugs 0.000 claims description 5
- 230000000181 anti-adherent effect Effects 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 4
- 239000002360 explosive Substances 0.000 claims description 4
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 229960001375 lactose Drugs 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229960001021 lactose monohydrate Drugs 0.000 claims description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 4
- -1 4-(4-trifluoromethylphenyl)phenyl unit Chemical group 0.000 claims description 3
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 238000010422 painting Methods 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 22
- 238000009472 formulation Methods 0.000 abstract description 8
- 102000016752 1-Alkyl-2-acetylglycerophosphocholine Esterase Human genes 0.000 abstract description 6
- 108010024976 Asparaginase Proteins 0.000 abstract description 6
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 102000006447 Phospholipases A2 Human genes 0.000 abstract description 2
- 108010058864 Phospholipases A2 Proteins 0.000 abstract description 2
- 239000007916 tablet composition Substances 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 description 25
- 239000002702 enteric coating Substances 0.000 description 15
- 238000009505 enteric coating Methods 0.000 description 15
- 239000012530 fluid Substances 0.000 description 11
- 239000012458 free base Substances 0.000 description 11
- 235000019645 odor Nutrition 0.000 description 11
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 7
- 239000004014 plasticizer Substances 0.000 description 7
- 230000002411 adverse Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 5
- 239000007900 aqueous suspension Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 4
- 229920001688 coating polymer Polymers 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000002662 enteric coated tablet Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 101000939517 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 2 Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 102100029643 Ubiquitin carboxyl-terminal hydrolase 2 Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 150000002367 halogens Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000005422 blasting Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000010951 particle size reduction Methods 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 2
- 229910052814 silicon oxide Inorganic materials 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- DTCCVIYSGXONHU-CJHDCQNGSA-N (z)-2-(2-phenylethenyl)but-2-enedioic acid Chemical compound OC(=O)\C=C(C(O)=O)\C=CC1=CC=CC=C1 DTCCVIYSGXONHU-CJHDCQNGSA-N 0.000 description 1
- DEWLEGDTCGBNGU-UHFFFAOYSA-N 1,3-dichloropropan-2-ol Chemical compound ClCC(O)CCl DEWLEGDTCGBNGU-UHFFFAOYSA-N 0.000 description 1
- RWHRFHQRVDUPIK-UHFFFAOYSA-N 50867-57-7 Chemical compound CC(=C)C(O)=O.CC(=C)C(O)=O RWHRFHQRVDUPIK-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- ZFIVKAOQEXOYFY-UHFFFAOYSA-N Diepoxybutane Chemical compound C1OC1C1OC1 ZFIVKAOQEXOYFY-UHFFFAOYSA-N 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- UGZICOVULPINFH-UHFFFAOYSA-N acetic acid;butanoic acid Chemical compound CC(O)=O.CCCC(O)=O UGZICOVULPINFH-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021417 amorphous silicon Inorganic materials 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- FLKPEMZONWLCSK-UHFFFAOYSA-N phthalic acid di-n-ethyl ester Natural products CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
- RVRKDGLTBFWQHH-UHFFFAOYSA-N yttrium zirconium Chemical compound [Y][Zr][Y] RVRKDGLTBFWQHH-UHFFFAOYSA-N 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0320522.6A GB0320522D0 (en) | 2003-09-02 | 2003-09-02 | Formulation |
| PCT/EP2004/009726 WO2005021002A1 (en) | 2003-09-02 | 2004-08-31 | Pharmaceutical formulation comprising a pyrimidine-a-one derivative coated with an enteric polymer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20061514L NO20061514L (no) | 2006-04-03 |
| NO333744B1 true NO333744B1 (no) | 2013-09-09 |
Family
ID=28686767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20061514A NO333744B1 (no) | 2003-09-02 | 2006-04-03 | Farmasoytisk formulering omfattende et pyrimidin-A-onderivat belagt med en enterisk polymer og fremgangsmate for fremstilling derav |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20060287346A1 (zh) |
| EP (1) | EP1663243B1 (zh) |
| JP (1) | JP4892346B2 (zh) |
| KR (1) | KR101115984B1 (zh) |
| CN (2) | CN102204891B (zh) |
| AR (1) | AR045547A1 (zh) |
| AT (1) | ATE422889T1 (zh) |
| AU (1) | AU2004268376B2 (zh) |
| BR (1) | BRPI0414038A (zh) |
| CA (1) | CA2537178C (zh) |
| CY (1) | CY1108953T1 (zh) |
| DE (1) | DE602004019547D1 (zh) |
| DK (1) | DK1663243T3 (zh) |
| ES (1) | ES2319124T3 (zh) |
| GB (1) | GB0320522D0 (zh) |
| HK (1) | HK1091734A1 (zh) |
| HR (1) | HRP20090147T3 (zh) |
| IL (1) | IL173910A (zh) |
| IS (1) | IS2677B (zh) |
| MA (1) | MA28033A1 (zh) |
| MX (1) | MXPA06002436A (zh) |
| MY (1) | MY139165A (zh) |
| NO (1) | NO333744B1 (zh) |
| NZ (1) | NZ545453A (zh) |
| PL (1) | PL1663243T3 (zh) |
| PT (1) | PT1663243E (zh) |
| RU (1) | RU2359660C2 (zh) |
| SI (1) | SI1663243T1 (zh) |
| TW (1) | TWI343257B (zh) |
| WO (1) | WO2005021002A1 (zh) |
| ZA (1) | ZA200601599B (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0320522D0 (en) * | 2003-09-02 | 2003-10-01 | Glaxo Group Ltd | Formulation |
| MX2009012188A (es) | 2007-05-11 | 2010-02-24 | Univ Jefferson | Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos. |
| KR101563753B1 (ko) | 2007-05-11 | 2015-10-27 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 피부 궤양의 치료 방법 |
| NZ595987A (en) | 2009-04-24 | 2014-02-28 | Iceutica Pty Ltd | A novel formulation of diclofenac |
| EP2651403B1 (en) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases |
| US9173884B2 (en) | 2011-11-30 | 2015-11-03 | Trustees Of Boston College | Inhibitors of phosphodiesterase 11 (PDE11) |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| EP3172211B1 (en) | 2014-07-22 | 2019-07-03 | GlaxoSmithKline Intellectual Property Development Limited | Tricyclic imidazo-pyrimidinone derivatives for the treatment of diseases mediated by lp-pla2 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3619570C1 (en) | 1986-06-11 | 1987-10-29 | Kneipp Werke Kneipp Mittel Zen | Coated garlic tablet |
| US4971805A (en) * | 1987-12-23 | 1990-11-20 | Teysan Pharmaceuticals Co., Ltd. | Slow-releasing granules and long acting mixed granules comprising the same |
| IT1227899B (it) * | 1988-12-23 | 1991-05-14 | Poli Ind Chimica Spa | Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni |
| TW209174B (zh) * | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
| JPH07223970A (ja) * | 1994-02-10 | 1995-08-22 | Tanabe Seiyaku Co Ltd | 消化管内適所放出製剤 |
| JP2917799B2 (ja) * | 1994-03-11 | 1999-07-12 | 田辺製薬株式会社 | 消化管内適所放出型製剤 |
| JP3185206B2 (ja) * | 1995-07-20 | 2001-07-09 | 田辺製薬株式会社 | 消化管下部放出型被覆カプセル製剤 |
| SG80553A1 (en) | 1995-07-20 | 2001-05-22 | Tanabe Seiyaku Co | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
| CN1147291C (zh) * | 1996-06-06 | 2004-04-28 | 拜福丹公司 | 用于口服制剂的含有藻酸的肠溶包衣 |
| DE59702733D1 (de) | 1996-08-15 | 2001-01-11 | Losan Pharma Gmbh | Gut schluckbare orale arzneiform |
| US6296876B1 (en) * | 1997-10-06 | 2001-10-02 | Isa Odidi | Pharmaceutical formulations for acid labile substances |
| AU3731699A (en) * | 1998-05-18 | 1999-12-06 | Takeda Chemical Industries Ltd. | Orally disintegrable tablets |
| CZ20011629A3 (cs) | 1998-11-12 | 2001-12-12 | Smithkline Beecham Plc | Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků |
| US6268385B1 (en) * | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
| ES2330552T3 (es) * | 2000-02-16 | 2009-12-11 | Smithkline Beecham Plc | Derivados de pirimidin-5-ona como inhibidores de ldl-pla2. |
| AUPQ672800A0 (en) * | 2000-04-06 | 2000-05-04 | Natraherbal Pty Ltd | Garlic supplement for deodoriser |
| CA2413330A1 (en) * | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
| ATE508725T1 (de) | 2001-06-20 | 2011-05-15 | Takeda Pharmaceutical | Verfahren zur herstellung von tabletten |
| JP5138856B2 (ja) * | 2001-06-20 | 2013-02-06 | 武田薬品工業株式会社 | 錠剤の製造方法 |
| RU2203671C1 (ru) | 2002-03-25 | 2003-05-10 | Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" | Противовирусный лекарственный препарат для перорального применения |
| GB0320522D0 (en) * | 2003-09-02 | 2003-10-01 | Glaxo Group Ltd | Formulation |
-
2003
- 2003-09-02 GB GBGB0320522.6A patent/GB0320522D0/en not_active Ceased
-
2004
- 2004-08-31 JP JP2006525098A patent/JP4892346B2/ja not_active Expired - Fee Related
- 2004-08-31 AR ARP040103126A patent/AR045547A1/es unknown
- 2004-08-31 WO PCT/EP2004/009726 patent/WO2005021002A1/en active Application Filing
- 2004-08-31 SI SI200431087T patent/SI1663243T1/sl unknown
- 2004-08-31 PT PT04764689T patent/PT1663243E/pt unknown
- 2004-08-31 US US10/570,335 patent/US20060287346A1/en not_active Abandoned
- 2004-08-31 KR KR1020067004235A patent/KR101115984B1/ko not_active IP Right Cessation
- 2004-08-31 EP EP04764689A patent/EP1663243B1/en active Active
- 2004-08-31 ES ES04764689T patent/ES2319124T3/es active Active
- 2004-08-31 BR BRPI0414038-9A patent/BRPI0414038A/pt not_active Application Discontinuation
- 2004-08-31 AT AT04764689T patent/ATE422889T1/de active
- 2004-08-31 CN CN201110102640XA patent/CN102204891B/zh not_active Expired - Fee Related
- 2004-08-31 MX MXPA06002436A patent/MXPA06002436A/es active IP Right Grant
- 2004-08-31 AU AU2004268376A patent/AU2004268376B2/en not_active Ceased
- 2004-08-31 RU RU2006110546/15A patent/RU2359660C2/ru not_active IP Right Cessation
- 2004-08-31 DE DE602004019547T patent/DE602004019547D1/de active Active
- 2004-08-31 CA CA2537178A patent/CA2537178C/en not_active Expired - Fee Related
- 2004-08-31 DK DK04764689T patent/DK1663243T3/da active
- 2004-08-31 CN CN2004800325934A patent/CN1874778B/zh not_active Expired - Fee Related
- 2004-08-31 TW TW093126106A patent/TWI343257B/zh not_active IP Right Cessation
- 2004-08-31 NZ NZ545453A patent/NZ545453A/en unknown
- 2004-08-31 PL PL04764689T patent/PL1663243T3/pl unknown
- 2004-09-01 MY MYPI20043561A patent/MY139165A/en unknown
-
2006
- 2006-02-23 IL IL173910A patent/IL173910A/en not_active IP Right Cessation
- 2006-02-23 ZA ZA200601599A patent/ZA200601599B/xx unknown
- 2006-03-10 MA MA28866A patent/MA28033A1/fr unknown
- 2006-03-20 IS IS8366A patent/IS2677B/is unknown
- 2006-04-03 NO NO20061514A patent/NO333744B1/no not_active IP Right Cessation
- 2006-11-09 HK HK06112335.3A patent/HK1091734A1/xx not_active IP Right Cessation
-
2009
- 2009-03-13 HR HR20090147T patent/HRP20090147T3/xx unknown
- 2009-04-08 CY CY20091100412T patent/CY1108953T1/el unknown
- 2009-06-05 US US12/478,934 patent/US8772303B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101849808B1 (ko) | 난용성 약물의 용해성 개선 제제 | |
| US8772303B2 (en) | Pharmaceutical formulation | |
| RU2318518C2 (ru) | Фармацевтическая композиция, обладающая антипролиферативным действием (варианты), способ ее получения и способы с ее использованием | |
| ZA200403281B (en) | Tamsulosin tablets. | |
| WO2006066961A1 (en) | Solid pharmaceutical composition comprising valsartan | |
| KR101820181B1 (ko) | 장용성 정제 | |
| JPH07145052A (ja) | 良好な溶解特性を有する医薬組成物 | |
| JP2009523784A (ja) | 酸不安定化合物の安定な医薬製剤およびその製造方法 | |
| AU2014225449B2 (en) | Stabilization of moisture-sensitive drugs | |
| AU2014224238A1 (en) | Formulations of organic compounds | |
| RU2593771C2 (ru) | Энтеросолюбильная таблетка | |
| US20220175766A1 (en) | Compositions and methods of treatment | |
| JP5669837B2 (ja) | 放出制御型の有核錠剤 | |
| WO2016012898A1 (en) | Oral pharmaceutical composition of lurasidone | |
| KR20060030480A (ko) | 플루바스타틴 및 카르멜로스 칼슘을 포함하는 정제 | |
| JP3944494B2 (ja) | フルバスタチン含有錠剤 | |
| JP2007077174A (ja) | フルバスタチン含有錠剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: GLAXO GROUP LTD, GB |
|
| MM1K | Lapsed by not paying the annual fees |